Multivariable analysis for serologic response
| Factor . | Odds ratio (95% CI; P-value) . |
|---|---|
| Initial vaccination cohort | |
| Treatment, naïve and B-cell-directed | |
| No B-cell-directed therapy, treatment naïve | 1 |
| No B-cell-directed therapy, not treatment naïve | 0.34 (0.15-0.78; P = .01) |
| B-cell-directed therapy | 0.19 (0.09-0.41; P < .0001) |
| Gender | |
| Male | 1 |
| Female | 1.54 (0.82-2.90; P = .18) |
| Age (as continuous variable) | 0.96 (0.93-0.99; P = .02) |
| Booster vaccination cohort | |
| Treatment-naïve status | |
| No | 1 |
| Yes | 1.86 (0.78-4.43; P = .16) |
| Gender | |
| Male | 1 |
| Female | 1.48 (0.63-3.49; P = .37) |
| Age (as continuous variable) | 0.97 (0.93-1.02; P = .20) |
| Factor . | Odds ratio (95% CI; P-value) . |
|---|---|
| Initial vaccination cohort | |
| Treatment, naïve and B-cell-directed | |
| No B-cell-directed therapy, treatment naïve | 1 |
| No B-cell-directed therapy, not treatment naïve | 0.34 (0.15-0.78; P = .01) |
| B-cell-directed therapy | 0.19 (0.09-0.41; P < .0001) |
| Gender | |
| Male | 1 |
| Female | 1.54 (0.82-2.90; P = .18) |
| Age (as continuous variable) | 0.96 (0.93-0.99; P = .02) |
| Booster vaccination cohort | |
| Treatment-naïve status | |
| No | 1 |
| Yes | 1.86 (0.78-4.43; P = .16) |
| Gender | |
| Male | 1 |
| Female | 1.48 (0.63-3.49; P = .37) |
| Age (as continuous variable) | 0.97 (0.93-1.02; P = .20) |